Wayne Markowitz - 14 Sep 2023 Form 4 Insider Report for Edwards Lifesciences Corp (EW)

Reporting relationship: GM & SVP, Surgical
Issuer ticker: EW
Reported as of: 14 Sep 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 15 Sep 2023, 17:01:15 UTC
Prior SEC filing: 25 Aug 2023
Next SEC filing: 09 May 2024
Source filing: View source filing
Reporting owner signature: Linda J. Park, Attorney-in-Fact

Key filing fact

Wayne Markowitz filed Form 4 for Edwards Lifesciences Corp (EW) on 15 Sep 2023.

Key facts

This page summarizes Wayne Markowitz's Form 4 filing for Edwards Lifesciences Corp (EW).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 15 Sep 2023, 17:01.

Change

Previous filing in this sequence was filed on 25 Aug 2023.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

EW transaction

Common Stock

Award

Transaction value: $0
Shares: +7,262
Change %
Price: $0.000000
Shares after: 7,262
Date: 14 Sep 2023
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

EW transaction Derivative

Employee Stock Option (Right to Acquire)

Award

Transaction value: $0
Shares: +19,256
Change %
Price: $0.000000
Shares after: 19,256
Date: 14 Sep 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 19,256
Exercise price: $74.02
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

These restricted stock units were granted on September 14, 2023 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested annually in equal installments over a period of four years commencing one year after the grant date.

Footnote F2

These options were granted on September 14, 2023 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable annually in equal installments over a period of four years commencing one year after the grant date.

SEC remarks

This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.